Company intelligence / Profile preview

AllgenBio

San Francisco, California, United Statesalgenbio.com ↗
Ownership
Private
Development stage
Other
01

Overview

Algen is developing a CRISPR platform for gene modulation, focusing on RNA signaling pathways to discover new therapies, particularly in oncology and immunology.

Therapeutic areas
OncologyImmunologyMetabolic Disorders
Modalities
CRISPR-based therapyRNA modulation
Industry
Biotech

Beyond the preview

Go deeper on AllgenBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllgenBio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call